We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
MaxCyte
Apeiron licence broadens the MaxCyte opportunityBerGenBio
AXL-erating towards new opportunitiesFutura Medical
AGM statement confirms MED3000 filings on trackBonesupport
Swings and roundaboutsHutchison China MediTech
General Atlantic invests $100m at 10% premiumHutchison China MediTech
ASCO 2020: savo and suru data drives regulatory progressMereo BioPharma
Private placement raises $70m (£56m)Nexstim
€2.3m rights issue is 273% subscribedFutura Medical
Nearing the critical point in Erectile DysfunctionMaxCyte
ASCO poster shows encouraging data for MCY-M11